• DiaDeep develops AI-based solutions to support pathologists in their decision-making, a cornerstone for treatment selection. 
• Several of DiaDeep’s algorithms dedicated to breast cancer are being marketed internationally through integration into Roche's digital pathology platform.

DiaDeep, an innovative French medtech company, announces an international collaboration with Roche to commercialize artificial intelligence (AI) tools to strengthen precision diagnostics in oncology. Through Roche's navify® Digital Pathology platform dedicated to digital pathology, pathologists will have access to DiaDeep’s algorithms for real-time quantification of breast cancer biomarkers (including Ki67, ER, PR, and HER2). 

Roche will market DiaDeep’s algorithms to public and private laboratories in the United States, the Middle East, and Europe. The revenues generated will enable DiaDeep to continue its investments in research and development, with a particular focus on predicting the progression of cancers such as melanoma. 

Digital pathology is a rapidly growing field globally, promising significant advancements in oncology. It involves digitizing human tissue slides to facilitate analysis and optimize workflow. It also enables the use of the latest technologies, including AI, to accelerate treatment decision making. While interpreting digital slides, DiaDeep’s algorithms provide pathologists with immediate biomarkers quantification results. Acting as a crucial assistant in pathologists' daily practice, DiaDeep’s technology aims to validate their decisions and free up time for analyzing complex cases. This critical work subsequently assists oncologists in choosing the most appropriate treatment, helping avoid over- or under-treatment of cancer patients.

A combination of expertise, a global deployment 

“Contributing to improving care and ensuring that every patient receives the most appropriate treatment by supporting pathologists, is DiaDeep’s priority,” said Sanae Salhi, co-founder and CEO of DiaDeep. “We are excited to be working alongside the Roche teams, in trust and shared expertise, to meet the needs of pathologists and contribute to the development of precision medicine. This strategic collaboration marks a turning point for the global distribution of our technology, ensuring that more patients receive the most appropriate treatments.”

Cancer remains one of the leading causes of death worldwide, responsible for nearly one in six deaths. Accurate diagnosis is a key element in choosing an appropriate and personalized treatment strategy according to the needs of each cancer patient. Breast cancer is both the most common and deadliest cancer among women, with 2.3 million cases and 670,000 deaths recorded globally in 2022. This public health challenge is naturally a priority for DiaDeep, whose commitment particularly focuses on women’s health.

About DiaDeep

DiaDeep is an independent medical technology company, founded in 2022 in Lyon (France) by two pathologists and two former AI researchers. DiaDeep’s mission is to enhance the precision of cancer diagnostics through AI, helping pathologists and oncologists improve patients' survival chances. DiaDeep is supported by 34 pathologist investors across different specialties who contribute to the development of its innovations. These collaborations help translate clinical needs into advanced technologies that can be used in routine practice. DiaDeep’s algorithms can be easily incorporated into the pathologist’s workflow, reducing the time spent on repetitive, time-consuming tasks and allowing more focus on complex cases. The goal is to ensure patients receive targeted and appropriate care, contributing to better overall outcomes.

Among its achievements, DiaDeep is the first French company to offer a comprehensive quantification tool for all biomarkers needed in pathology for breast cancer diagnosis. DiaDeep’s technology has been recognized through five presentations at ASCO and several partnerships with public and private institutions at both national and international levels. The company receives support from IHP Group, one of France’s leading independent pathology laboratories and the first user of DiaDeep’s technology. 

Every patient matters, every decision counts!

For more information: www.diadeep.com

‍